Hyperacute direct thrombus imaging using computed tomography and gold nanoparticles

Kim, Dong Eog; Kim, Jeong Yeon; Sun, In Cheol; Schellingerhout, Dawid; Lee, Su Kyoung; Ahn, Cheol Hee; Kwon, Ick Chan; Kim, Kwangmeyung

doi:10.1002/ana.23849

Cited by 45 publications

(58 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT imaging was able to visualize plaques 30 minutes after induction of the thrombus and 5 minutes after injection of particles and also 48 hours and 3 weeks later without further injection of AuNP. Application of tissue plasminogen activator, the clinical preference for clot breakdown, led to a decrease in CT signal at the clot areas [69]. A follow-up study added fibrintargeting peptides to the formulation.…”

Section: Thrombus Targeted Goldmentioning

confidence: 99%

Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology

Mahan

Doiron

2018

Journal of Nanomaterials

115

View full text Add to dashboard Cite

Computed tomography (CT) is among the most popular medical imaging modalities due to its high resolution images, fast scan time, low cost, and compatibility with all patients. CT scans of soft tissues require the localization of imaging contrast agents (CA) to create contrast, revealing anatomic information. Gold nanoparticles (AuNP) have attracted interest recently for their use as CT CA due to their high X-ray attenuation, simple surface chemistry, and biocompatibility. Targeting molecules may be attached to the particles to allow for the targeting of specific cell types and disease states. AuNP can also be readily designed to incorporate other imaging contrast agents such as rare earth metals and dyes. This review summarizes the current state-of-the-art knowledge in the field of AuNP used as X-ray and multimodal contrast agents. Primary research is analyzed through the lens of structure-propertyfunction to best explain the design of a particle for a given application. Design specification of particles includes size, shape, surface functionalization, composition, circulation time, and component synergy. Key considerations include delivery of a CA payload to the site of interest, nontoxicity of particle components, and contrast enhancement compared to the surrounding tissue. Examples from literature are included to illustrate the strategies used to address design considerations.

show abstract

Section: Thrombus Targeted Goldmentioning

confidence: 99%

Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology

Mahan

Doiron

2018

Journal of Nanomaterials

115

View full text Add to dashboard Cite

show abstract

“…Furthermore, combining such systems with multicolor CT allowed distinguishing at once macrophages accumulation and calcification [71]. Glycol chitosan (GC) coating has also been demonstrated to enhance retention and compatibility of gold nanoparticles (Au-NPs) [72]. Furthermore, its affinity for fibrin makes it a coating of choice for thrombus targeting.…”

Section: Gold Nanoparticlesmentioning

confidence: 99%

Nanomedicine for the molecular diagnosis of cardiovascular pathologies

Juenet

Varna

Aid‐Launais

et al. 2015

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…The study showed that these nano particles allowed both the detection of primary and recurrent thrombi, and the monitoring the therapeutic efficacy of thrombolysis with tissue plasminogen activator (tPA). Due to a long circulating half-life, GC-gold nano particles remained available for entrapment into fibrin matrix for up to 3 weeks, allowing repetition or ongoing monitoring of thrombogenesis and thrombolysis (50). Given the need of rapid and reliable in vivo assessment of the thrombotic risk in patients with cardiovascular diseases in order to improve the diagnosis, risk stratification, and management of thrombotic syndromes, those systems represent a very attractive platform for use in clinical practice.…”

Section: Estimating the Burden Of Thrombosismentioning

confidence: 99%

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Cicha¹,

Garlichs²,

Alexiou³

2014

European Journal of Nanomedicine

View full text Add to dashboard Cite

Abstract:Recent years brought about a widespread interest in the potential applications of nanotechnology for the diagnostics and the therapy of human diseases. With its promise of disease-targeted, patient-tailored treatment and reduced side effects, nanomedicine brings hope for millions of patients suffering of non-communicable diseases such as cancer or cardiovascular disorders. However, the emergence of the complex, multicomponent products based on new technologies poses multiple challenges to successful approval in clinical practice. Regulatory and development considerations, including properties of the components, reproducible manufacturing and appropriate characterization methods, as well as nanodrugs' safety and efficacy are critical for rapid marketing of the new products. This review discusses the recent advances in cardiovascular applications of nanotechnologies and highlights the challenges that must be overcome in order to fill the gap existing between the promising bench trials and the successful bedside applications.

show abstract

Hyperacute direct thrombus imaging using computed tomography and gold nanoparticles

Cited by 45 publications

References 35 publications

Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology

Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology

Nanomedicine for the molecular diagnosis of cardiovascular pathologies

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Contact Info

Product

Resources

About